Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewC14TKL-1 is an endogenous human tachykinin-like peptide and potent agonist for NK1 receptors (EC50 = 1 nM).
分子量 | 1406.7 |
公式 | C63H98N20O13S2 |
序列 |
RHRTPMFYGLM (Modifications: Met-11 = C-terminal amide) |
储存 | Desiccate at -20°C |
PubChem ID | 90488729 |
InChI Key | MMNLXHSWHPGRFE-MRQSSJIPSA-N |
Smiles | [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
参考文献是支持产品生物活性的出版物。
Jiang et al (2003) PepPat, a pattern-based oligopeptide homology search method and the identification of a novel tachykinin-like peptide. Mamm.Genome 14 341 PMID: 12856286
关键词: C14TKL-1, C14TKL-1 supplier, Endogenous, NK1, agonists, Tachykinin, Receptors, Neurokinin, Chromosome14, tachykinin-like, peptide1, Chromosome, 14, peptide, 1, Receptor, 1939, Tocris Bioscience
目前没有该产品的评论。 Be the first to review C14TKL-1 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
Written by Sonia Tucci, Lynsay Kobelis and Tim Kirkham, this review provides a synopsis of the increasing number of peptides that have been implicated in appetite regulation and energy homeostasis; putative roles of the major peptides are outlined and compounds available from Tocris are listed.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.